Torrent Pharmaceuticals Limited has informed the Exchange regarding Outcome of Board Meeting held on May 22, 2026.
TORNTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Torrent Pharmaceuticals reported standalone revenue of ₹10,712 crores for FY26, up 10.6% from ₹9,682 crores in FY25. Net profit grew 16.1% to ₹2,192 crores from ₹1,888 crores. The Board approved a clean (unmodified) audit opinion from BS R & Co. LLP. Key highlights include a final dividend of ₹9 per share (₹38 total including ₹29 interim already paid) and approval to raise up to ₹5,000 crores via QIP. The company completed its ₹12,537 crore acquisition of J.B. Chemicals & Pharmaceuticals (JB Pharma) in January 2026, gaining 48.8% stake. Total debt surged significantly to fund the acquisition, with debt-equity ratio rising to 1.68 from 0.34, though operating cash flow remained healthy at ₹2,731 crores.
Strong earnings growth and shareholder returns signal operational strength despite heavy acquisition-related debt. The large QIP authorization suggests management may look to reduce leverage. The JB Pharma acquisition adds scale to the pharmaceutical portfolio, though near-term integration costs and higher debt levels warrant monitoring.